Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...

Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...

BOSTON—Ourania Tatsis, Executive Vice President and Chief Regulatory and Quality Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a $116 billion market cap biotech company currently trading near ...

Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped it generate billions of dollars in ...

The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive potential of opioids.

HOUSTON, January 22, 2025--(BUSINESS WIRE)--Vertex Energy, Inc. ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, together with its affiliates ...

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration has approved JOURNAVX, an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor ...

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in November, despite some highly positive news. The U.S. Food and Drug Administration (FDA) approved ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...